Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Apr 2028
Next term end
9
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2043.
US 11,168,124
CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
Oct 31, 2036
US 12,404,526
ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
Jun 6, 2038
US 12,084,693
Codon-Optimized Acid Alpha-Glucosidase Expression Cassettes and Methods of Using Same
Nov 20, 2041
US 12,290,574
Optimized Promoter Sequences, Intron-Free Expression Constructs and Methods of Use
May 4, 2042
201820242030203620422043
30 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2036 · High confidence
Also notable
Ends Apr 2028 · High confidence
Also notable
Ends Sep 2040 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends May 2039 · High confidence
CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS
US 11,168,124
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2036.
Genetic Suppression and Replacement
US 8,257,969
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2028.
COLUMN-BASED FULLY SCALABLE rAAV MANUFACTURING PROCESS
US 11,702,639
Granted 2023. Computed term ends 2040.
Rab Escort Protein Potency Assay
US 10,633,689
Granted 2020. Computed term ends 2038.
Relative Potency Assay for Viral Vector Encoding Isomerohydrolases
US 12,359,239
Granted 2025. Too new for citation comparison; protection runs to 2039.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for COLUMN-BASED FULLY SCALABLE rAAV MANUFACTURING PROCESS (US 11,702,639) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Rab Escort Protein Potency Assay (US 10,633,689) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Plasmid Free Aav Vector Producing Cell Lines | 1 in force | to Jan 2043 |
| Optimized Promoter Sequences, Intron-Free Expression Constructs and Methods of Use | 1 in force | to May 2042 |
| Codon-Optimized Acid Alpha-Glucosidase Expression Cassettes and Methods of Using Same | 1 in force | to Nov 2041 |
| COLUMN-BASED FULLY SCALABLE rAAV MANUFACTURING PROCESS | 1 in force | to Sep 2040 |
| Relative Potency Assay for Viral Vector Encoding Isomerohydrolases | 1 in force | to May 2039 |
| ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION | 1 in force | to Jun 2038 |
| CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS | 1 in force | to Oct 2036 |
| Genetic Suppression and Replacement | 1 in force | to Apr 2028 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,257,969 | Genetic Suppression and Replacement In force · High confidence | In force | High confidence | |
| US 11,168,124 | CpG REDUCED FACTOR VIII VARIANTS, COMPOSITIONS AND METHODS AND USES FOR TREATMENT OF HEMOSTASIS DISORDERS In force · High confidence | In force | High confidence | |
| US 10,633,689 | Rab Escort Protein Potency Assay In force · High confidence | In force | High confidence | |
| US 12,404,526 | ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION In force · High confidence | In force | High confidence | |
| US 12,359,239 | Relative Potency Assay for Viral Vector Encoding Isomerohydrolases In force · High confidence | In force | High confidence | |
| US 11,702,639 | COLUMN-BASED FULLY SCALABLE rAAV MANUFACTURING PROCESS In force · High confidence | In force | High confidence | |
| US 12,084,693 | Codon-Optimized Acid Alpha-Glucosidase Expression Cassettes and Methods of Using Same In force · High confidence | In force | High confidence | |
| US 12,290,574 | Optimized Promoter Sequences, Intron-Free Expression Constructs and Methods of Use In force · High confidence | In force | High confidence | |
| US 12,799,501 | Plasmid Free Aav Vector Producing Cell Lines In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 1 patent ended · 30 applications pending · 18 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.